SCHEMBL1376178

SCHEMBL1376178

CC(C)OC(=O)CNc1ccc(O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.49
CA2 P00918 6/20 0.49
CA12 O43570 5/20 0.49
CA7 P43166 5/20 0.49
CA9 Q16790 5/20 0.49
CA14 Q9ULX7 5/20 0.49
HSP90AA1 P07900 2/20 0.48
MAPT P10636 5/20 0.44
ALDH1A1 P00352 4/20 0.43
KMT2A Q03164 4/20 0.43
NLRP1 Q9C000 1/20 0.43
AKR1B10 O60218 1/20 0.42
AKR1B1 P15121 1/20 0.42
TSHR P16473 2/20 0.42
MIF P14174 1/20 0.42
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16554940 0.88 CA1 (0.42) CA1CA2CA12CA7CA9
SCHEMBL28156315 0.86 MAPT (0.57) CA1CA2CA12CA9HSP90AA1
SCHEMBL28157052 0.85 MAPT (0.61) MAPTALDH1A1KMT2ANLRP1TSHR
SCHEMBL28156318 0.85 HPGD (0.44) MAPTALDH1A1KMT2ANLRP1TSHR
SCHEMBL4591681 0.84 TSHR (0.56) MAPTALDH1A1KMT2ANLRP1TSHR
SCHEMBL28156311 0.83 NPC1 (0.59) CA1CA2CA12CA9MAPT
Hydrochloric Acid SCHEMBL7439811 0.83 TSHR (0.54) MAPTALDH1A1KMT2ANLRP1TSHR
SCHEMBL28251114 0.82 LOXL2 (0.44) CA1CA2CA12CA7MAPT
SCHEMBL1713162 0.82 CA1 (0.51) CA1CA2CA12CA7CA9
SCHEMBL28383137 0.81 EGLN1 (0.46) CA1CA2CA12CA7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1603549-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS Yu, Ruey J., Dr. (US) 2005-12-14 EP claimed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US claimed
US-20040220264-A1 Bioavailability and improved delivery of acidic pharmaceutical drugs YU RUEY J 2004-11-04 US claimed
WO-2004082628-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS YU RUEY J (US) 2004-09-30 WO claimed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP claimed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US claimed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO claimed
US-8753856-B2 Stable biocatalysts of penicillin acylase as gel aggregates and the process of manufacture thereof FERMENTA BIOTECH LTD. (US) 2014-06-17 US disclosed
US-20110287509-A1 STABLE BIOCATALYSTS OF PENICILLIN ACYLASE AS GEL AGGREGATES AND THE PROCESS OF MANUFACTURE THEREOF MIKROBIOLOGICKY USTAV AVCR V.V.I. (CZ) 2011-11-24 US disclosed
EP-2344635-A1 STABLE BIOCATALYSTS OF PENICILLIN ACYLASE AS GEL AGGREGATES AND THE PROCESS OF MANUFACTURE THEREOF Fermenta Biotech Limited (IN) 2011-07-20 EP disclosed
WO-2010055527-A1 STABLE BIOCATALYSTS OF PENICILLIN ACYLASE AS GEL AGGREGATES AND THE PROCESS OF MANUFACTURE THEREOF FERMENTA BIOTECH LIMITED (IN) 2010-05-20 WO disclosed
EP-1603549-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS Yu, Ruey J., Dr. (US) 2005-12-14 EP disclosed
US-6824786-B2 TOPICAL APPLYING COSMETIC YU RUEY J (US) 2004-11-30 US disclosed
US-20040220264-A1 Bioavailability and improved delivery of acidic pharmaceutical drugs YU RUEY J 2004-11-04 US disclosed
WO-2004082628-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS YU RUEY J (US) 2004-09-30 WO disclosed
EP-1455734-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES Yu, Ruey J., Dr. (US) 2004-09-15 EP disclosed
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives YU RUEY J (US) 2003-06-12 US disclosed
WO-2003045338-A1 COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES YU RUEY J (US) 2003-06-05 WO disclosed
EP-0640014-A1 SEPARATION METHOD NOVO NORDISK A/S (DK) 1995-03-01 EP disclosed
WO-1993023164-A1 SEPARATION METHOD NOVO NORDISK A/S (DK) 1993-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030108496-A1 Compositions comprising phenyl-glycine derivatives GRHPR, ARL1, SUCLG1 CA1 3257/4885CA2 1324/4885CA12 3784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.